Startup Explores Gene-Editing Technology for Embryos

Why it matters locally: Origin Genomics, a startup based in New York City, is developing gene-editing technology for embryos, positioning New York at the forefront of this emerging and ethically complex scientific field.

NEW YORK — Origin Genomics, a startup based in New York City, is developing technology designed to edit disease-causing genes within human embryos. The company states its objective is to demonstrate that the potential advantages of its gene-editing method outweigh any associated risks. Cathy Tie, founder and CEO of Origin Genomics, supervises the replenishment of nutrients for cells used in testing the company's technology. Researchers are employing these cells to evaluate the effectiveness of their gene-repairing techniques.